Biocon to start selling breast cancer drug in India in February
Fp Archives • . MUMBAI (Reuters) - Biocon Ltd( BION.NS ) said its generic version of Roche's( ROG.VX ) Herceptin breast cancer treatment would be available to patients in India from the first week of February. Bangalore-based Biocon jointly developed biosimilar trastuzumab, which received the Indian drug regulator's marketing approval in November, with U.S.-based Mylan Inc. About 150,000 people are diagnosed with breast cancer every year in India, of which 25 percent are eligible for treatment with trastuzumab, Biocon said.
